Quizartinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: More Patients Make It to Transplant, but Are There Any Other Benefits?

Transplant Cell Ther. 2021 Feb;27(2):99-100. doi: 10.1016/j.jtct.2021.01.002. Epub 2021 Jan 6.

Author

Bradley D Hunter¹

Affiliation

¹ Director, Immune Effector Cell Therapy; Assistant Professor, Blood and Marrow Transplant, Intermountain Healthcare. Electronic address: brad.hunter@imail.org.

PMID: 33781547
DOI: 10.1016/j.jtct.2021.01.002

No abstract available

MeSH terms

Benzothiazoles / therapeutic use
Humans
Leukemia, Myeloid, Acute* / drug therapy
Phenylurea Compounds*
fms-Like Tyrosine Kinase 3 / genetics

Substances

Benzothiazoles
Phenylurea Compounds
quizartinib
FLT3 protein, human
fms-Like Tyrosine Kinase 3